HOOKIPA Pharma Inc
NASDAQ:HOOK

Watchlist Manager
HOOKIPA Pharma Inc Logo
HOOKIPA Pharma Inc
NASDAQ:HOOK
Watchlist
Price: 0.89 USD 0.91%
Market Cap: 11m USD

HOOKIPA Pharma Inc
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

HOOKIPA Pharma Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
HOOKIPA Pharma Inc
NASDAQ:HOOK
Income from Continuing Operations
-$73.3m
CAGR 3-Years
1%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$2.4B
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$8.1B
CAGR 3-Years
35%
CAGR 5-Years
46%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$7B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
$3.7B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$4.6B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
23%
No Stocks Found

HOOKIPA Pharma Inc
Glance View

Market Cap
10.7m USD
Industry
Biotechnology

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company is headquartered in New York City, New York and currently employs 131 full-time employees. The company went IPO on 2019-04-18. The firm is engaged in developing an immunotherapeutic based on its arenavirus platform, which is designed to target and amplify a T cell and immune response to disease. Its replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its pipeline candidates include HB-200, HB-300, HB-700, HB-101, HB-101 and HBV Therapy. The HB-200 program consists of its arenaviral-based immunotherapies for the treatment of patients with advanced/metastatic cancers caused by 16-positive (HPV16+). Its lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papillomavirus HPV16+ cancers in a Phase I/II clinical trial. Its non-replicating prophylactic Cytomegalovirus vaccine candidate, HB-101, is for patients awaiting kidney transplantation in Phase II clinical trial.

HOOK Intrinsic Value
2.61 USD
Undervaluation 66%
Intrinsic Value
Price

See Also

What is HOOKIPA Pharma Inc's Income from Continuing Operations?
Income from Continuing Operations
-73.3m USD

Based on the financial report for Mar 31, 2025, HOOKIPA Pharma Inc's Income from Continuing Operations amounts to -73.3m USD.

What is HOOKIPA Pharma Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-10%

Over the last year, the Income from Continuing Operations growth was -54%. The average annual Income from Continuing Operations growth rates for HOOKIPA Pharma Inc have been 1% over the past three years , -10% over the past five years .

Back to Top